학술논문
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
Document Type
Article
Author
Budde, Lihua E.; Olszewski, Adam J.; Assouline, Sarit; Lossos, Izidore S.; Diefenbach, Catherine; Kamdar, Manali; Ghosh, Nilanjan; Modi, Dipenkumar; Sabry, Waleed; Naik, Seema; Mehta, Amitkumar; Nakhoda, Shazia K.; Smith, Stephen D.; Dorritie, Kathleen; Jia, Ting; Pham, Song; Huw, Ling-Yuh; Jing, Jing; Wu, Hao; Ead, Wahib S.; To, Iris; Batlevi, Connie Lee; Wei, Michael C.; Chavez, Julio C.
Source
Nature Medicine; 20230101, Issue: Preprints p1-11, 11p
Subject
Language
ISSN
10788956; 1546170X
Abstract
Relapsed/refractory aggressive large B cell lymphoma (LBCL) remains an area of unmet need. Here we report the primary analysis of a phase 1b/2 trial of outpatient mosunetuzumab (a CD20xCD3 T-cell-engaging bispecific antibody) plus polatuzumab vedotin (an anti-CD79B antibody–drug conjugate) in relapsed/refractory LBCL. The phase 2 component is a single arm of an ongoing multi-arm trial. The primary endpoint during dose expansion was independent review committee (IRC)-assessed best overall response rate. Secondary endpoints included investigator-assessed overall response rate, complete response, duration of response, progression-free survival and overall survival. At data cutoff, 120 patients were enrolled (22 dose escalation, 98 dose expansion). The primary endpoint was met during dose expansion, with IRC-assessed best overall response rate and complete response rates of 59.2% (58/98; 95% confidence interval (CI): 48.8–69.0) and 45.9% (45/98; 95% CI: 35.8–56.3), respectively (median follow-up, 23.9 months). Median duration of complete was not reached (95% CI: 20.5–not estimable (NE)). Median progression-free survival was 11.4 months (95% CI: 6.2–18.7). Median overall survival was 23.3 months (95% CI: 14.8–NE). Across dose escalation and expansion, the most common grade 3 or higher adverse events were neutropenia (25.0%, 30/120) and fatigue (6.7%, 8/120). Any-grade cytokine release syndrome occurred in 16.7% of patients. These data demonstrate that mosunetuzumab plus polatuzumab vedotin has a favorable safety profile with highly durable responses suitable as second-line therapy in transplant-ineligible relapsed/refractory LBCL. ClinicalTrials.gov identifier: NCT03671018.